ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

デキサメチルフェニデート

Dexmethylphenidate

HCID 154101
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
40431-64-9
標準SMILES
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
InChIKey
DUGOZIWVEXMGBE-CHWSQXEVSA-N
分子式
C14H19NO2
平均分子量
233.31 g/mol
単同位体質量
233.14157885

概要

Dexmethylphenidate is a methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate. It has a role as an adrenergic agent. It is an enantiomer of a methyl (S)-phenyl[(S)-piperidin-2-yl]acetate.

名称と識別子

優先名称
Dexmethylphenidate
IUPAC
methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
現地名
デキサメチルフェニデート
英語名
dexmethylphenidate
分子式
C14H19NO2
分子量
233.31

名称と別名

Dexmethylphenidated-threo-Methylphenidate(+)-threo-Methylphenidate40431-64-9dexmetilfenidatoAttenadeD-TMPM32RH9MFGPdexmethylphenidatummethyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetateCHEBI:51860methyl (R)-phenyl[(R)-piperidin-2-yl]acetate
名称をさらに表示
デキサメチルフェニデートデクスメチルフェニデートd-threo-FormDexaMethylphenedateDexmethylphenidate D9D-threo-Methylphenidate DISCONTINUED, offer M3256752-Piperidineacetic acid, α-phenyl-, methyl ester, (αR,2R)-
DTXSID70893769methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate2-Piperidineacetic acid, alpha-phenyl-, methyl ester, (alphaR,2R)-METHYL (2R)-PHENYL((2R)-PIPERIDIN-2-YL)ACETATEmethyl (R)-phenyl((R)-piperidin-2-yl)acetatemethyl (2R)-2-phenyl-2-((2R)-piperidin-2-yl)acetateRefChem:56469Methylphenidate d-threo-

データベース識別子

CAS
40431-64-9

物性

構造計算による物性

XLogP
0.2
極性表面積
38.3 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
4
重原子数
17
形式電荷
0
複雑度
249

実験および物理化学的性質

Drugs · 2 件

DEA NFLIS-Drug Category -> Piperidines/PEA

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

Human DrugsBreast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents
Melting Point>203
Physical DescriptionSolid

物理化学的性質

沸点
327.6 · 327.6±17.0 °C(Predicted)
比重(密度)
1.07 · 1.070±0.06 g/cm3(Predicted)
酸解離定数(Pka)
9.51 · 9.51±0.10(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Exposure Routes11-52%
Toxicity Summary · 1 件

Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.

Signs and Symptoms · 1 件

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

dexmethylphenidate

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataOral, Mouse: LD<sub>50</sub>=190mg/kg

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein Binding12-15% of dexmethylphenidate is protein bound. However, other studies have observed 15.2±5.2% protein binding in children and 16.2±1.1% in adults.
PharmacodynamicsDexmethylphenidate is the d-enantiomer of methylphenidate. This enantiomer is more pharmacologically active than the racemic mixture and may block norepinephrine and dopamine reuptake in synapses.
Mechanism of Action · 1 件

Methylphenidate inhibits dopamine and norepinephrine reuptake transporters in synapses, especially in the thalamus and striatum. One study shows no detectable difference in the caudal prefrontal cortex of treated or untreated monkeys, though multiple rat studies show activity on the prefrontal cortex. Imaging of human brains after administration of methylphenidate shows changes to blood flow of various regions of the brain including the striatum, supplementary motor area, and posterior parietal cortex.

Biological Half-LifeThe mean terminal half life is approximately 2.2 hours. However other studies have shown 3.8-3.9 hours, or 5.96 hours after intravenous administration and 5.69 hours following an oral dose.
Metabolism/Metabolites · 2 件

Dexmethylphenidate is metabolised to the inactive metabolite ritalinic acid by carboxylesterase 1A1 in the liver. Other minor pathways metabolise dexmethylphenidate to the inactive metabolites 6-oxo-methylphenidate and p-hydroxy-methylphenidate which are de-esterified and conjugated into other unknown metabolites.

epatic, methylphenidate is metabolized primarily by de-esterification to ritalinic acid (&alpha;-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity. Route of Elimination: Renal Half Life: 2-4 hours

FDA Pharmacological Classification · 5 件

M32RH9MFGP

DEXMETHYLPHENIDATE

Established Pharmacologic Class [EPC] - Central Nervous System Stimulant

関連反応

16 件
反応記録を作成
HRID 241544 の反応式
HRID 241544生成物として
HRID 242139 の反応式
HRID 242139生成物として
HRID 587133 の反応式
HRID 587133生成物として
HRID 599388 の反応式
HRID 599388生成物として
HRID 599389 の反応式
HRID 599389反応物として
HRID 874176 の反応式
HRID 874176生成物として
HRID 1019622 の反応式
HRID 1019622生成物として
HRID 1020445 の反応式
HRID 1020445生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
PubChem CID
154101
DTXSID
DTXSID70893769
ChEMBL
CHEMBL827
ChEBI
CHEBI:51860
UNII
M32RH9MFGP
Nikkaji
J343.157F

Physiologic Effects [PE] - Central Nervous System Stimulation

Dexmethylphenidate is a Central Nervous System Stimulant. The physiologic effect of dexmethylphenidate is by means of Central Nervous System Stimulation.

MeSH Pharmacological Classification · 2 件

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Absorption, Distribution and Excretion · 4 件

Taking dexmethylphenidate with or without food does not affect patients in a clinically relevant way. 90% of an oral dose is absorbed but as a result of hepatic first pass metabolism, oral bioavailability of dexmethylphenidate is 23% compared to l-methylphenidate with an oral bioavailability of 5%. Maximum concentration is generally reached in 1-1.5 hours.

Dexmethylphenidate is mainly eliminated renally. After 48 hours, 90% of the dose is collected in the urine and 3.3% is collected from feces.

2.65L/kg when administered intravenously.

0.40L/hr/kg following an intravenous dose and a renal clearance of 0.005L/hr/kg.

Cellular LocationsMembrane

用途と製造

UsesDexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment.

応用分野

使用Treatment of attention deficit/hyperactivity disorder.

補足説明

定義ChEBI: A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.